Optimizing Multiple Sclerosis Care in the General Neurology Setting Interactivity Module

Released On
July 7, 2022

Expires On
July 7, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Neurology, Pharmacy, Primary Care

Topic(s)
Multiple Sclerosis

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.

This activity is supported by independent educational grants from Bristol Myers Squibb and Genentech.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 contact hours of nursing continuing professional development credit (NCPD) (1.0 in the area of pharmacology)
  • Pharmacists — 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit.

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of general neurology physicians, PAs, nurse practitioners, nurses, and other healthcare professionals involved in the treatment of patients with MS.

Program Overview

A series of case reviews that provides participants with scenarios where one or more errors, unsafe practices, or underutilization of newer therapies when appropriate have occurred. The goal is to provide real-life examples of suboptimal treatment for MS patients and to challenge non-MS specialists to identify areas for improvement.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the efficacy and safety data for newer MS therapies to facilitate evidence-based care
  • Identify pre-treatment requirements or recommendations for newer MS therapies
  • Develop individualized treatment plans that consider appropriate and safe use of newer therapies
  • Apply effective team-based strategies that include communication with MS specialists to promote optimal patient outcomes
  • Review evidence-based approaches to MS diagnosis and early initiation of appropriate therapy

Faculty

Allen C. Bowling, MD, PhD

Director, NeuroHealth Institute

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

The CMSC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

The CMSC designates this activity for a maximum of 1.0 NCPD credit (1.0 in the area of pharmacology).

Pharmacists

This knowledge-based activity, UAN JA4008165-9999-22-030-H01-P, qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit.

Disclosures of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC requires that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. It is the policy of the CMSC to mitigate all relevant financial disclosures from planners, faculty, and other persons that can affect the content of this CE activity. For this activity, all relevant disclosures have been mitigated. CMSC seeks to ensure independence, objectivity, balance, and scientific rigor in all educational programs and to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in healthcare and not those of a commercial interest.

Faculty Disclosures

The program faculty reported the following relevant financial relationships with ineligible companies:

Allen C. Bowling, MD, PhD
  • Royalty: Springer Publishing
  • Consulting Fees: Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen, Greenwich Biosciences, Novartis Pharmaceuticals Corporation
  • Speakers Bureau: Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen
  • Contracted Research: EMD Serono

Activity Staff Disclosures

June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have disclosed no relevant financial relationships.

All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.

The planners, reviewers, editors, staff, CME committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.

Instructions for Participation and Credit

This activity is an online enduring material. There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CME information, reading the material, completing the pre-test, studying the educational activity and completing the post-test and the evaluation form. Upon completion of the evaluation, your certificate will be made available immediately. Click on "View Certificate" and print the certificate for your records.

The estimated time to complete the activity is 60 minutes.

This activity was originally released on July 7, 2022 and is eligible for credit through July 7, 2023.

Course Viewing Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.co to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Our Policy on Privacy

The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CE activities viewed and the post-test and evaluation results for CE credit. This information is provided to activity collaborators for the purposes of CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.

Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.

Disclosure of Unlabeled Use

CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

For questions about this activity, please contact Catamount Medical Education at info@catmeded.com.